Additional groups have investigated the pathogenic effects of anti-Caspr2 IgG exposure in a maternal–fetal transfer model, administering purified anti-Caspr2 IgG derived from sera of a male patient with Caspr2 autoimmune encephalitis to dams, daily, starting from embryonic day E12.5 [43]. The gene discussed is CNTNAP2; the disease is autoimmune encephalitis.